Loading...
Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study
van der Eerden,B. de Rooij,B.H. Schouten,L.J. Boll,D. van Hamont,D. Vos,M.C. Ezendam,N.P.M.
van der Eerden,B.
de Rooij,B.H.
Schouten,L.J.
Boll,D.
van Hamont,D.
Vos,M.C.
Ezendam,N.P.M.
Abstract
Objective This study assessed the health-related quality of life (HRQo) of women surviving a borderline ovarian tumor (BOT) in comparison with early-stage ovarian cancer survivors treated surgically alone and with a matched cancer-free population. Methods Survivors of BOT and ovarian cancer were invited in two Dutch cross-sectional, population-based studies. Ovarian cancer survivors with tumor stage I who were treated surgically only were included. A random sample from the cancer-free population was matched on sex, age and education to the sample of BOT survivors. The EORTC QLQ-C30 (version 3.0) and the EORTC QLQ-OV28 were completed by the cancer-free population and the BOT and ovarian cancer survivors in study 1 and 2. The Hospital Anxiety and Depression Scale (HADS) was only completed by the cancer-free population and the survivors of BOT and ovarian cancer in study 1. BOT survivors were compared to early-stage ovarian cancer survivors and the general population using linear regression analyses and effect sizes regarding clinical importance. Results 83 BOT (42%), 88 early-stage ovarian cancer survivors (52%), and 82 women from the general population were included. In most HRQoL domains, BOT survivors were not significantly different from early-stage ovarian cancer survivors and the cancer-free population, except that BOT survivors reported significantly less insomnia than early-stage ovarian cancer survivors and more dyspnea than the cancer-free population (small clinical difference). Conclusion In general, BOT survivors' HRQoL lies between the HRQoL of early-stage ovarian cancer survivors and of the cancer-free population, but clinical effect sizes between the groups were mostly only trivial.
Description
Date
2024-10
Journal Title
Journal ISSN
Volume Title
Publisher
Research Projects
Organizational Units
Journal Issue
Keywords
Borderline ovarian tumors, Early-stage disease, HRQoL, Ovarian cancer, Survivors, SDG 3 - Good Health and Well-being
Citation
van der Eerden, B, de Rooij, B H, Schouten, L J, Boll, D, van Hamont, D, Vos, M C & Ezendam, N P M 2024, 'Quality of life among borderline ovarian tumor survivors : A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study', Gynecologic Oncology, vol. 189, pp. 111-118. https://doi.org/10.1016/j.ygyno.2024.07.681